Dr. Reddy’s Laboratories launches Toripalimab in India

28 Nov 2024 Evaluate

Dr. Reddy’s Laboratories has launched Toripalimab in India. Toripalimab is a New Biological Entity (NBE). It is the only immuno-oncology drug approved by various regulatory authorities around the world such as the United States Food and Drug Administration (USFDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). 

In 2023, the company entered into a license and commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab. Under this agreement, the company obtained exclusive rights to develop and commercialise Toripalimab in 21 countries including India, South Africa, Brazil and various countries in Latin America. Additionally, the agreement allows the company to expand the scope of the license to cover Australia, New Zealand and nine other countries. 

With this launch by the company, India becomes the third country in the world after China and the United States to receive access to this next generation PD-1 inhibitor 1. The company will market it under the brand name Zytorvi in India.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.


Dr. Reddys Lab Share Price

1263.35 -5.70 (-0.45%)
29-Dec-2025 11:48 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1726.00
Dr. Reddys Lab 1263.35
Cipla 1499.65
Zydus Lifesciences 904.65
Lupin 2088.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×